Click image to view full size image
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with a IC50 of 0.94 nM[1]. [(66)Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation[2].
Specifications
|
Sequence one letter code |
cyclo(RGDfK) |
|
Sequence three letter code |
cyclo(-Arg-Gly-Asp-D-Phe-Lys) |
|
CAS No |
161552-03-0 |
|
Molecular Formula |
C27H41N9O7 |
|
Molecular Weight |
603.68 |
|
Modification |
N/A |
|
Purity |
Peak Area by HPLC ≥98% |
|
Form |
Lyophilized |
|
Long Storage |
- 20 °C or below |
| For Research Use Only. | |
References:
1. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
2. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
http://www.biorunstar.com/